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Abstract
Background: Application of repetitive transcranial magnetic stimulation (rTMS) for treating obsessive-compulsive
disorder (OCD) has been promising and approved by the Food and Drug Administration in 2018, but effects differ
between patients. Knowledge about clinical predictors of rTMS response may help to increase clinical efficacy but is
not available so far.
Methods: In a retrospective study, we investigated the efficacy of rTMS over the dorsolateral prefrontal cortex
(DLPFC) or supplementary motor area (SMA) in 65 pharmaco-resistant OCD outpatients recruited for rTMS
treatment from July 2015 to May 2017. Patients received either SMA rTMS (n = 38) or bilateral DLPFC rTMS (n = 27)
in case of reporting higher affective and depressive symptoms in addition to the primary OCD symptoms. OCD
symptoms and depression/anxiety states were measured at baseline (before the 1st session) and after the 20th
session of rTMS. Additionally, we performed a binary logistic regression analysis on the demographic and clinical
variables based on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) 3-factor and 2-factor models and
individual items to investigate potential predictors of rTMS response.
Results: Patients’ scores in Y-BOCS and Beck anxiety/depression inventories were significantly decreased following
rTMS treatment. 46.2% of all patients responded to rTMS, based on the criterion of at least a 30% reduction in Y-
BOCS scores. There was no significant difference between response rates of patients in DLPFC and SMA groups. No
significant demographic predictors of rTMS efficacy were identified. The factors “obsession severity”, “resistance” and
“disturbance” and the “interference due to obsessions” and “resistance against compulsions” items of the Y-BOCS
significantly predicted response to rTMS.
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Conclusions: In patients with less intrusive/interfering thoughts, and low scores in the “obsession severity”,
“disturbance”, and “resistance” factors, rTMS might have superior effects. Identifying clinical and non-clinical
predictors of response is relevant to personalize and adapt rTMS protocols in pharmaco-resistant OCD patients.
Interpretation of rTMS efficacy should be done with caution due to the lack of a sham intervention condition.
Keywords: Obsessive-compulsive disorder (OCD), Repetitive transcranial magnetic stimulation (rTMS), Clinical
predictors, Demographic predictors, Yale-Brown obsessive-compulsive scale (Y-BOCS)
Background
With a lifetime prevalence of 1–3% [1], obsessive-
compulsive disorder (OCD) is a frequent and disabling psy-
chiatric disorder. It is characterized by intrusive, anxiety-
provoking, interfering thoughts (obsessions), and associated
repetitive behaviors (compulsions) [2]. OCD, which is fre-
quently undertreated [3], is remarkably heterogeneous in
etiology, symptoms, subtype and treatment response [4, 5].
As a result, approximately 40–60% of OCD patients remain
treatment-refractory to current first-line therapies [6–8],
possibly due to the sub-optimal and non-adapted treatment
in non-responders. Accordingly, the development of novel
therapeutic strategies based on an improved understanding
of OCD pathophysiology is relevant [3, 9].
Previous studies in humans and animal models suggest
that functional abnormalities of the cortico-striato-
thalamo-cortical circuits and supplementary motor area
(SMA) might be central pathophysiological components of
OCD [10–13]. The dorsolateral and dorsomedial prefrontal
cortex (DLPFC, DMPFC), orbitofrontal cortex (OFC) and
anterior cingulate cortex are also proposed to be involved.
Involvement of such a diverse regions suggests that the
pathophysiology of OCD is heterogeneous which might be
an important source of variability in the efficacy of conven-
tional OCD treatments. Neuromodulatory treatments in-
volving brain stimulation can modulate respective target
regions in OCD and other disorders with abnormalities re-
lated to these regions such as drug addiction, depression,
schizophrenia, borderline personality disorder, and ADHD
[14–19]. They have also potential for individualization via
the informed choice of respective targets. Repetitive trans-
cranial magnetic stimulation (rTMS) is a non-invasive brain
stimulation technique proposed as a promising method for
treating OCD via altering excitability of DLPFC and SMA
[20–22]. TMS alters neural activity and excitability of tar-
geted brain regions [23, 24]. Repetitive application of
TMS (i.e., rTMS) can induce neuroplastic after-effects in
target areas, and depending on the specific stimulation
protocol, the effects can be inhibitory or excitatory [25, 26].
These neuroplastic effects are the main rationale behind
the clinical therapeutic effects of rTMS [26, 27].
Previous rTMS studies reported an average response
rate of 35% in OCD patients, defined as a minimum of
25–40% reduction in post-treatment symptoms [20].
Higher response rates and augmented efficacy were re-
cently reported in patients with a more homogenous
pathological profile, including common pathophysio-
logical deficits [9, 28, 29]. This implies the potential rele-
vance of predictors of effective rTMS treatment in OCD,
and accordingly the need for personalizing rTMS treat-
ment based on the pathophysiological and clinical pro-
files of the patients [28]. In this line, recent reviews of
rTMS studies show that brain state-dependent modula-
tory effects of rTMS are an additional parameter that
may potentially affect rTMS effects [30], and taking this
factor into account might improve treatment outcomes
in patients who usually develop treatment-resistant ill-
ness subtypes. Moreover, different cortical regions have
been targeted in previous studies with mixed results
[31–35], leaving the question of which cortical regions
to stimulate unanswered.
While specific stimulation parameters and neurobio-
logical predictors of response to rTMS treatment have
been investigated in OCD [9, 36], the importance of clin-
ical and demographic factors has not been systematically
explored yet. These factors, especially clinical predictors,
play a potentially key role in accurately selecting patients
for rTMS treatment. Findings from rTMS studies in other
neuropsychiatric disorders suggest that specific symptoms,
subtypes or psychological states can distinguish between
responders and non-responders to rTMS. We recently in-
vestigated clinical and demographic predictors of rTMS
response in depressive disorders and found that cognitive-
affective symptoms, as compared to somatic symptoms,
significantly predict response to rTMS [37]. Another study
found that nonresponders to rTMS treatment for depres-
sion had markedly higher baseline anhedonia symptoms
[38]. Although recent studies tried to predict response to
rTMS treatment in OCD based on electrophysiological
measures [33], clinical predictors of response so far have
not been explored.
In the present study, we aimed to investigate the efficacy
of rTMS over two potentially involved cortical regions (i.e.,
SMA and DLPFC) for reducing OCD symptoms. More im-
portantly, we aimed to identify potential clinical and demo-
graphic predictors, that could distinguish between rTMS
responders and nonresponders in OCD. Based on previous
findings about the efficacy of rTMS in OCD patients [20],
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we expected to observe a response rate of 35–55%, based
on a 30% reduction of the Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS) baseline score (responder cri-
terion). With regard to clinical predictors of rTMS re-
sponse, we aimed to identify predictability of the rTMS
effects in OCD by clinical variables (based on Y-BOCS fac-
tors and items) and demographic characteristics.
Methods
Study design
We retrospectively analyzed a dataset of pharmaco-
resistant OCD outpatients who received an rTMS treat-
ment between July 2015 and May 2017. Patients were re-
ferred to the Atieh Clinical Neuroscience Center in Tehran,
Iran, to receive rTMS. The center admits patients with
psychiatric disorders (e.g. depression, OCD), neurological
disorders (e.g. stroke, dementia), and pediatric neurodeve-
lopmental disorders (e.g. attention-deficit hyperactivity dis-
order, autism, learning disabilities).
Participants
Sixty-five pharmaco-resistant OCD outpatients (Mean
age = 32.25, SD = 10.23, 35 females) were included in
this report. 69 patients were initially included, but
four patients did not either finish the treatment
course without any reported reason or meet the mini-
mum symptom severity to be included. Of 65 patients
38 patients underwent SMA rTMS protocol and 27
patients received DLPFC rTMS protocol (see Table 2
for more details). A priori sample size calculation
showed that based on a medium effect size (f = 0.5)
which is suggested for NIBS studies [39], a critical p-
value of 0.05, and a critical power level of 0.95, the
required sample size is 42. The OCD diagnosis was
based on the Structural Clinical Interview by a li-
censed psychiatrist according to the DSM 5 diagnostic
criteria, confirmed by patient scores on the Y-BOCS
[40]. The inclusion criteria were: (1) 18–65 years old,
(2) current OCD diagnosis based on DSM-5 (3) mod-
erate to severe OCD score on the Y-BOCS (scores 16
and higher) (4) response failure to previous or current
use of medication/psychotherapy (response failure was
defined as scores > 16 at Y-BOCS despite at least two
SSRI trials of adequate dosage and duration) and (5)
stable medication regimen 8-10 weeks before the
intervention and unchanged during the treatment (4–
6 weeks) [9]. Exclusion criteria included previous
treatment with electroconvulsive therapy, and pres-
ence or history of psychosis, substance abuse, suicide
attempt and/or active suicide ideation, neurological
disorder, epilepsy, seizures, and head injury or loss of
consciousness. According to the safety criteria for
rTMS [41], patients with implanted devices, metal
bodies, cardiac arrhythmia, unstable medical condi-
tions, or pregnancy, were also excluded. 51 patients
were taking selective serotonin reuptake inhibitors
(SSRIs) during rTMS treatment, and the remaining
patients had a history of SSRI medication use. Most
Table 1 Demographic information of participants
Variable Category n Response (≥30%) p-value
Yes No
Sample size (n) 65 30 35
Comorbidity (yes) 34 12 22 0.06
On medication (yes) 51 24 27 0.55
Protocol SMA rTMS 38 16 22 0.30
DLPFC rTMS 27 14 13
Age Mean (SD) 32.25 (10.23) 32.67 (9.44) 31.89 (10.99) 0.76
Gender Male 30 14 16 0.56
Female 35 16 19
Education Diploma or lower 24 10 14 0.65
Associate degree 7 3 4
Bachelor degree 22 11 11
Masters degree 6 2 4
Not reported 6 4 2
Marital status Single 26 10 16 0.71
Married 33 17 16
Divorced or separated 6 3 3
Note: SMA Supplementary motor area, rTMS repetitive transcranial magnetic stimulation, DLPFC dorsolateral prefrontal cortex, SD Standard Deviation. Between
group (responders vs non-responders) differences in demographic variables were explored using chi-square analysis or Fisher’s exact test for categorical variables
and t-tests for continuous variables. Response rate defined as at least 30% reduction of the Yale-Brown Obsessive-Compulsive Scale post-intervention.
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of the patients had no history of psychotherapy. All
patients provided written informed consent to treat-
ment. Demographic and clinical characteristics of pa-
tients are summarized in Tables 1 and 2.
rTMS treatment parameters
RTMS was administrated with a Neuro MS rTMS device
(Neurosoft, Russia) using a 70-mm figure-of-8-shaped
coil (air film coil). Active motor threshold (AMT) was
defined as the minimum stimulus intensity that pro-
duced a liminal motor evoked response during active
contraction of the abductor policies brevis muscle (APB)
(at about 20% maximum contraction) [42]. Motor
threshold determination was based on visual inspection
of the respective finger movement. Patients received ei-
ther SMA rTMS, or bilateral DLPFC rTMS. For SMA
rTMS, the coil was positioned over the SMA, which was
localized via the 10–20 EEG system, and defined as 15%
of the distance between nasion and inion anterior to the
vertex in the sagittal plane [43]. In the SMA-rTMS
protocol, TMS was delivered at 120% of AMT. Stimula-
tion frequency was 1 Hz, which was applied for 30 min,
resulting in a total of 1800 pulses per session. Stimula-
tion was performed once a day, 3 days per week for 7
weeks, resulting in 20 sessions (36,000 pulses over 20
sessions). For DLPFC rTMS, all patients received bilat-
eral stimulation, based on results of previous studies that
showed mixed effects of unilateral rTMS [35]. For
DLPFC rTMS, the position of the coil was 5 cm anterior
along a parasagittal line from the site of optimum APB
stimulation [44]. Stimulation was delivered over the right
and left DLPFC respectively. First, 15 min of 1 Hz stimu-
lation (inhibitory) at 120% AMT, resulting in a total of
900 pulses per session, was applied over the right
DLPFC, resulting in a total of 18,000 pulses over 20 ses-
sions. The left DLPFC was stimulated immediately after-
wards by applying 10 Hz stimulation (excitatory) at
120% AMT via 60 stimulation trains of a duration of 5 s
each, with 10 s inter-train intervals, resulting in a total of
3000 pulses per session in 15min (60,000 pulses over 20
sessions).
Clinical procedure
All patients underwent a baseline clinical assessment
with the Y-BOCS, Beck Anxiety Inventory (BAI) [45]
and Beck Depression Inventory (BDI-II) [46] 1 week be-
fore rTMS treatment (pre-treatment) and after the 20th
session of rTMS (post-treatment) (Fig. 1). Participants
Table 2 Group (SMA vs DLPFC rTMS) charactristics
Variable Category n rTMS protocol p-value 95%CI
SMA rTMS DLPFC rTMS lower upper
SMA DLPFC SMA DLPFC
Sample size (n) 65 38 27
Comorbidity (n) 34 20 14 0.09
On medication (n) 51 21 30 0.77
rTMS reponse Yes 30 21 9 0.12
No 35 17 18
Age Mean (SD) 32.25 (10.23) 31.58 (10.64) 33.19 (9.75) 0.54 27.03 39.49 33.00 44.38
Gender Male 30 17 13 0.80
Female 35 21 14
Education Diploma or lower 24 14 10 0.89
Associate degree 7 4 3
Bachelor degree 22 13 9
Masters degree 6 3 3
Not reported 6 4 2
Marital status Single 26 15 11 0.94
Married 33 20 13
Divorced or separated 6 3 3
BL Y-BOCS Mean (SD) 22.75 (6.66) 23.52 (7.37) 21.66 (5.44) 0.27 18.74 26.52 17.07 23.88
BL BAI Mean (SD) 25.90 (11.01) 24.71 (10.15) 27.59 (12.10) 0.32 20.19 30.74 20.47 33.83
BL BDI-II Mean (SD) 22.64 (8.95) 21.84 (9.86) 23.77 (7.54) 0.39 18.36 27.07 21.70 29.98
Note: SMA Supplementary motor area, rTMS repetitive transcranial magnetic stimulation, DLPFC dorsolateral prefrontal cortex, SD Standard Deviation, Y-BOCS Yale-
Brown Obsessive-Compulsive Scale, BAI Beck Anxiety Inventory, BDI-II Beck Depression Inventory; Group differences based on the applied protocol (SMA vs DLPFC
rTMS) in demographic variables were explored using chi-square analysis or Fisher’s exact test for categorical variables and t-tests for continuous variables
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received SMA or DLPFC rTMS based on the clinical im-
pression of a psychiatrist according to the reported
symptoms. Although no significant difference was found
in participants’ depressive symptoms based on the ques-
tionnaires, those who reported more depressive symp-
toms were allocated to DLPFC rTMS. Baseline symptom
severity for inclusion was defined as a score of 16 or
higher on the Y-BOCS (Mean = 22.20, SD = 7.01), which
is the cut-off criterion for moderate OCD (8–15 mild,
16–23 moderate, 24–31 severe, 32–40 extreme). Treat-
ment response was defined as a reduction of at least 30%
in the Y-BOCS total score, based on several previous
studies [33, 47] and is suggested to represent a relevant
clinical improvement (i.e., improvement of Clinical Glo-
bal Impression). Although 35% of symptom reduction is
taken as “response” criterion in other studies [48], we
chose a more liberal criterion to achieve a more bal-
anced response distribution for the binary regression
analysis. The protocol was conducted in accordance with
the latest version of the Declaration of Helsinki and was
approved by the Institutional Review Board and ethical
committee at the local university and Atieh Clinical
Neuroscience Center.
Measures
Y-BOCS
The Y-BOCS is the most widely used clinician-rated
interview for assessing OCD symptom severity with
adequate psychometric characteristics (i.e., inter-rater re-
liability and predictive validity) [49]. It contains 10 items,
and each item is rated from 0 (no symptoms) to 4 (ex-
treme symptoms). The Y-BOCS is sensitive to change,
and during-treatment score reductions are valid out-
come indicators [49]. Therefore, results of this question-
naire are suited as clinical predictors of treatment
response, as shown by previous rTMS studies [37]. The
Y-BOCS items weigh obsessions and compulsions
equally. Obsession items assess spent time on obsessions
(item 1), interference (item 2) and distress (item 3) due
to obsessive thoughts, resistance against obsessions (item
4) and degree of control over obsessive thoughts (item
5). Items 6–10 assess respective variables (i.e., spent
time, interference, distress, resistance, and degree of
control) for compulsions respectively.
BAI & BDI-II
Both BAI and BDI-II consist of 21 items, which are rated
on a Likert scale ranging from 0 to 3, resulting in raw
scores ranging from 0 to 63, and are indicative for the
presence of anxiety or depression. The BAI is well suited
to monitor anxiety treatment outcomes [50], and the ob-
tained anxiety state is correlated with OCD symptoms
[51, 52]. Similarly, the BDI-II scores are associated with
OCD symptoms [52] in line with the fact that around
one-third of OCD patients suffer from comorbid
Fig. 1 The procedure of rTMS treatment. Note: Y-BOCS = Yale-Brown Obsessive-Compulsive Scale; BAI = Beck Anxiety Inventory; BDI-II = Beck
Depression Inventory; SMA = supplementary motor area; DLPFC = dorsolateral prefrontal cortex
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depression [53]. Both measures have adequate psycho-
metric properties [54, 55].
Statistical analysis
Data analyses were conducted using IBM, SPSS (version
24). In order to examine rTMS efficacy, mixed model
analysis of variance (ANOVA) was conducted with
“protocol” (DLPFC rTMS vs. SMA rTMS) as the
between-subject and time (pre-intervention vs. post-
intervention) as the within-subject factors. Mauchly’s
test was used to evaluate sphericity of the data and in
case of violation of sphericity, degrees of freedom were
corrected using the Greenhouse–Geisser estimates of
sphericity. The normality and homogeneity of the data
were confirmed by Shapiro-Wilk and Levin tests, re-
spectively. For identifying demographic and clinical pre-
dictors of response to rTMS treatment, participants
were split into “responders” and “non-responders” and a
binary logistic regression was conducted. To control for
potential confounding variables, we added these vari-
ables into the model, as the model adjusts itself for po-
tential confounders using adjusted odds-ratio [56]. The
goodness of fit was evaluated by the Hosmer-Lemeshaw
statistic, which also adjusts for potential covariates, and
the variable selection was based on the “stepwise for-
ward” strategy due to a large set of potential independ-
ent variables. The model was run in 2 steps in all
analyses. Independent variables were age, gender, educa-
tion, marital status (as demographic variables), and clin-
ical factors were selected based on the 3-factor and 2-
factor model of Y-BOCS, as well as all 10 items of the
Y-BOCS that are assumed to measure different OCD
symptoms. Given that the Y-BOCS items are not inde-
pendent of each other, we first defined 3 and 2 factors -
based on respective models derived from single items
[57, 58] - as clinical predictors in separate analyses.
Afterward and in a separate analysis, each individual
item was treated as a potential clinical predictor of re-
sponse to rTMS treatment. We ran the regression ana-
lysis separately for the demographic variables, Y-BOCS
factors, and the Y-BOCS items in order not to increase
the number of predictors as suggested [59]. To diagnose
multicollinearity, we used the linear regression proced-
ure and entered all covariates in the model. A signifi-
cance level of p < 0.05 was used for all statistical
comparisons.
Data availability
The datasets used and/or analyzed for the present study
are available from the corresponding author upon rea-
sonable request.
Results
Participant characteristics
The mean age of responders (N = 30, 16 females) and
nonresponders (N = 35, 19 females) was 32.67 (9.44),
and 31.89 (10.99) years old, respectively. The groups
did not differ significantly with respect to demo-
graphic variables (e.g. age, gender, education, marital
status), comorbidity rate, medication use, baseline de-
pression and applied intervention protocol (i.e., SMA
vs DLPFC rTMS) (Table 1). A comparison of the
same demographic variables, treatment response, and
baseline OCD, anxiety and depressive scores between
groups that received SMA, or vs DLPFC rTMS
showed no significant differences neither (Table 2).
Data overview
RTMS was well-tolerated by most patients. No severe
adverse effects were reported except for occasional head-
ache and dizziness, which usually disappeared spontan-
eously within 1–2 days. In thirty patients (46.2%), at least
a 30% reduction of their Y-BOCS scores after 20 ses-
sions of rTMS was observed. The remaining patients
(53.8%) were defined as non-responders. Specifically, in
patients that underwent SMA rTMS, 16 out of 38
(42.1%) responded to rTMS treatment, which is equiva-
lent to 53.3% of all responders. From the patients re-
ceived bilateral DLPFC protocol, 14 out of 27 (51.9%)
responded to the rTMS treatment, which is equivalent
to 46.7% of all responders (Fig. 2 C). Descriptive statis-
tics of patients’ scores in the Y-BOCS, BAI, and BDI-II
scales before and after treatment are displayed in Table 3
and Fig. 2.
Effectiveness of rTMS
DLPFC vs SMA rTMS
No significant main effect of protocol (F(1) = 1.71, p <
0.19, ηp
2 = 0.02) or time × protocol interaction (F(1) =
0.06, p < 0.80, ηp
2 = 0.01) emerged, indicating no signifi-
cant dfference between the protocols (i.e., SMA vs
DLPFC rTMS) in reducing OCD symtoms. No signifi-
cant interaction of time × protocol or main effect of
protocol were found neither for the BAI scores (F(1) =
0.94, p < 0.33, ηp
2 = 0.015; F(1) = 0.43, p < 0.51, ηp
2 =
0.007), and depression symptoms measured by the BDI-
II (F(1) = 0.01, p < 0.99, ηp
2 = 0.001; F(1) = 1.01, p < 0.32,
ηp
2 = 0.016) (See Table 4).
Overall efficacy
The results of overall ANOVA revealed a significant
main effect of time on the Y-BOCS overall score in
all patients (F(1) = 53.51, p < 0.01, ηp
2 = 0.46), indicating
a significant reduction of OCD symptoms after 20
sessions regardless of the stimulation protocol patiens
underwent. Bonferroni-corrected post hoc paired t-
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tests for pre-post values showed significant differences
in the Y-BOCS scores (t = 7.43, p < 0.01). With regard
to anxiety and depression states, the ANOVA results
similarly showed a significant main effect of time on
BAI (F(1) = 34.90, p < 0.01, ηp
2 = 0.357), and BDI-II
scores (F(1) = 19.97, p < 0.01, ηp
2 = 0.241). Again, the
Bonferroni-corrected post hoc t-tests for pre-post
values showed significant differences in the BAI (t =
5.83, p < 0.01) and BDI-II (t = 4.57, p < 0.01) scores.
Predictors of rTMS treatment
Results of the multicollinearity analysis showed a vari-
ance inflation factor (VIF) of higher than 3 for only 2
dependent variables, however, a VIF around 10 is indica-
tive for high multicollinearity [60]. The VIFs for items
1–9 were 2.60, 2.07, 3.05, 1.35, 2.98, 2.86, 3.16, 2.61, and
2.32, respectively. Since some of the individual Y-BOCS
items are not completely independent from each other,
we first conducted binary regression analyses on the fac-
tors extracted from the Y-BOCS items. We entered the
factors from the three-factor [58] and two-factor [57]
models separately as the factors from the model share
similarities (Table 5). In the 3-factor model [58], regres-
sion results show that the “severity of obsessions”
(Wald = 8.19) and “resistance of symptoms” factors
(Wald = 5.16) were two significant predictors of rTMS
treatment response in OCD. The overall model was sta-
tistically significant (χ2 = 26.64, p < 0.01, df = 2) with a
Nagelkerke’s R2 of 0.45 and prediction success of 80%
(28 of 35) and 70% (21 of 30) for non-responders and re-
sponders respectively. Regarding the 2-factor model [57],
the overall model was statistically significant (χ2 = 23.71,
p < 0.01, df = 1) with a Nagelkerke’s R2 of 0.41 and pre-
diction success of 74.3% (26 of 35) and 76.7% (23 of 30)
for non-responders and responders respectively. The
Wald criterion revealed the “disturbance” factor (items
Fig. 2 Mean score of Y-BOCS, BAI, and BDI-II before and after rTMS treatment in responders and nonresponders to rTMS (a). Mean score of Y-BOCS,
BAI, and BDI-II before and after rTMS treatment in participants who received SMA or DLPFC rTMS (b). Percentage of response (c) and percentage
of OCD symptoms decrease (d) in all patients and based on the intervention protocol. In graphs C and D, only post-intervention scores are
compared. Note: Y-BOCS = Yale-Brown Obsessive-Compulsive Scale; BAI = Beck Anxiety Inventory; BDI-II = Beck Depression Inventory; * =
statistically significant; ns = non-significant; All error bars represent standard error of the mean (S.E.M). Pairwise comparisons were conducted
using the Bonferroni-corrected post hoc t-test
Rostami et al. BMC Psychiatry          (2020) 20:372 Page 7 of 13
2,3,7,8) as the only significant clinical factor in predict-
ing rTMS response in OCD.
We then conducted a separate binary logistic regres-
sion on the Y-BOCS items. The overall model was statis-
tically significant (χ2 = 27.74, p < 0.01, df = 2), indicating
that clinical predictors significantly distinguished non-
responders from responders to rTMS treatment. Nagelk-
erke’s R2 of 0.46 indicates a relatively moderate relation-
ship between predictors and rTMS response, indicating
that the model explained 46% of the variance of rTMS
response in OCD patients. Prediction success was 82.9%
(29 of 35) and 73.3% (22 of 30) for non-responders and
responders, respectively. The Wald criterion identified
items 2 (interference due to obsessive thought) and 9
(resistance against compulsions) of the Y-BOCS as the
two significant clinical predictors of rTMS treatment re-
sponse in OCD. In other words, it was shown that an in-
crease of 1 unit in response to items 2 and 9, would
increase the risk of not responding to rTMS treatment
3.8 and 2.4 times (Odds ratio), respectively (Table 5).
The item-based results show a pattern of response simi-
lar to the regression results of the Y-BOCS factors. We
also conducted a separate binary logistic regression ana-
lysis on demographic predictors. No demographic factor,
including age (p = 0.83), gender (p = 0.23), and educa-
tional level (p = 0.11) as well as other clinical variables
such as comorbidity (p = 0.81) and medication use (p =
Table 3 Means and SDs of OCD, anxiety and depressive scores before and after rTMS treatment based on the response (responders
vs nonresponders) and protocol (SMA rTMS vs DLPFC rTMS)
Measure Response pre-intervention post-intervention Pre vs post
M (SD) t (sig) M (SD) t (sig) t (sig)
Y-BOCS responders 22.90 (6.94) −0.32 (0.75) 12.73 (6.01) −5.38 (0.01) 12.39 (0.001)
non-responders 22.62 (6.50) 21.02 (5.97) 2.35 (0.025)
total 22.75 (6.66) 17.20 (7.25) 7.43 (0.001)
SMA rTMS 23.52 (7.37) 1.11 (0.27) 18.13 (7.95) 1.23 (0.22) 3.06 (0.003)
DLPFC rTMS 21.66 (5.44) 15.88 (6.04) 3.69 (0.001)
BAI responders 27.00 (9.72) 0.60 (0.54) 15.13 (7.51) −0.71 (0.47) 5.84 (0.001)
non-responders 24.97 (12.06) 18.37 (10.65) 2.95 (0.005)
total 25.91 (11.01) 16.87 (9.41) 5.83 (0.001)
SMA rTMS 24.71 (10.15) −1.04 (0.30) 16.94 (9.95) 0.07 (0.94) 3.36 (0.001)
DLPFC rTMS 27.59 (12.10) 16.77 (8.77) 3.76 (0.001)
BDI-II responders 22.50 (9.78) −0.20 (0.84) 16.43 (9.93) −0.12 (0.91) 3.17 (0.003)
non-responders 22.77 (8.32) 17.28 (9.16) 3.25 (0.002)
total 22.64 (8.95) 16.89 (9.46) 4.57 (0.001)
SMA rTMS 21.84 (9.86) −0.85 (0.39) 16.07 (9.28) −82 (0.41) 2.62 (0.010)
DLPFC rTMS 23.77 (7.54) 18.03 (9.77) 2.42 (0.019)
Y-BOCS Yale-Brown Obsessive-Compulsive Scale, BAI Beck Anxiety Inventory, BDI-II Beck Depression Inventory, M Mean, SD Standard Deviation. Significant results
are highlighted (p ≤ 0.05) in bold
Table 4 Results of the Mixed model ANOVAs for effects of protocol (SMA vs DLPFC rTMS) and time (pre-intervention, post-
intervention) on OCD, anxiety and depressive symptoms in pharmacoresistant OCD patients
Measure Source df Mean square F p-value partial eta2
Y-BOCS Time 1,63 958.15 53.51 0.001 0.46
Protocol 1,63 132.82 1.70 0.197 0.01
Time*protocol 1,63 1.15 0.06 0.803 0.05
BAI Time 1,63 2727.96 34.90 0.001 0.36
Protocol 1,63 58.06 0.43 0.511 0.18
Time*protocol 1,63 73.49 0.94 0.336 0.01
BDI-II Time 1,63 1044.46 19.97 0.001 0.24
Protocol 1,63 119.65 1.01 0.318 0.02
Time*protocol 1,63 0.004 0.01 0.993 0.01
Y-BOCS Yale-Brown Obsessive-Compulsive Scale, BAI Beck Anxiety Inventory, BDI-II Beck Depression Inventory. Significant results are highlighted (p ≤ 0.05) in bold
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0.86), significantly predicted response to rTMS in OCD
patients.
Discussion
In this retrospective study, we examined rTMS thera-
peutic efficacy in 65 pharmaco-resistant OCD outpa-
tients. An overall significant reduction in OCD
symptoms and anxiety / depressive states were observed
after 20 sessions of rTMS. 46.2% of the patients
responded to rTMS treatment (based on the criterion of
30% reduction of Y-BOCS baseline scores), and a signifi-
cant reduction of OCD symptoms was observed in the
whole patient group, including non-responders (less
than 30% symptom reduction). No significant difference
was found in treatment efficacy between the intervention
protocols (i.e., bilateral DLPFC vs. SMA rTMS). Regard-
ing the predictors of rTMS response, no demographic
predictor (i.e., age, gender, marital status) was identified.
Both obsession and compulsion -related items/factors
were related to response rate. “Obsessions severity”, “dis-
turbance”, and “resistance” were the clinical factors that
significantly predicted response to rTMS. In this line,
items 2 and 9 of the Y-BOCS (i.e., “interference due to
obsessive thought” and “resistance against compulsions”)
were the most relevant clinical predictors of response to
rTMS based on individual items regression analysis.
The response rate to rTMS in our OCD sample is in
line with previous studies. The first meta-analysis in the
field included 10 randomized controlled rTMS studies
(with ≥25–40% reduction in Y-BOCS scores) and re-
ported a 35% response rate in 120 OCD patients that re-
ceived rTMS [20]. Other recent studies reported a
response rate of 40–55% based on the 30% reduction ver-
sus Y-BOCS baseline score criterion [31–34]. In all of
these studies, rTMS was applied over the DLPFC, SMA or
pre-SMA except for [33], that targeted the medial PFC.
Another recent meta-analysis showed that the therapeutic
outcome of DLPFC vs SMA rTMS protocols is not signifi-
cantly different, which was confirmed by our study results
[36]. A recent rTMS study in OCD patients, which tar-
geted the DMPFC, reported, however, a success rate of
50% with ≥50% reduction in post-treatment Y-BOCS
scores specifically in those OCD patients with hypercon-
nectivity of fronto-striatal circuits [9].
This pattern of results suggests that response to rTMS
in OCD patients depends on the pathophysiology of tar-
get region/s and the appropriate modulation of the in-
volved regions. OCD is a heterogeneous disorder not
only at the symptom, but also the pathophysiological
level [4, 5, 61]. It can be speculated that nonresponders
to rTMS in our study resemble OCD subtypes with spe-
cific pathophysiological features, including involved
cortico-subcortical regions in deeper brain areas (e.g.
Table 5 Binary logistic regression analysis of significant clinical predictors (Y-BOCS items and factors) of response to rTMS treatment
Predictors Nagelkerke R2 0.46(item-based
analysis)
Mean±SD item
score in NR and (R)
Predicted group β Wald df p Odd ratio
(e β)
95% CI
Lower Upper
Individual Y-BOCS factors Non-responders
Interference due to obsessive thoughts (2) 2.11 ± 0.93 (1.17 ± 0.69) 1.34 9.89 1 0.002 3.83 1.66 8.86
Resistance against compulsions (9) 2.0 ± 1.11 (1.0 ± 0.94) 0.86 7.41 1 0.006 2.38 1.27 4.45
Constant −3.31 13.06 1 0.01 0.03
Time occupied by obsession (1) 2.40 ± 1.03 (1.53 ± 0.86) 0.10
Distress associated with obsessions (3) 2.51 ± 0.74 (1.77 ± 1.07) 0.14
Resistance against obsessions (4) 1.69 ± 0.90 (1.30 ± 0.79) 0.29
Control over obsessions (5) 2.51 ± 0.88 (1.67 ± 0.84) 0.21
Time spent on compulsions (6) 1.77 ± 0.97 (1.07 ± 0.74) 0.68
Interference due to compulsions (7) 1.86 ± 1.06 (0.97 ± 0.92) 0.96
Distress associated with compulsions (8) 2.03 ± 1.04 (1.03 ± 1.15) 0.81
Control over compulsions (10) 2.17 ± 1.12 (1.23 ± 0.97) 0.67
2-factor Model [57] Disturbance
factor (items, 2,3,7,8)
8.51 ± 2.86 (4.93 ± 2.67) 0.51 13.41 1 0.001 1.67 1.27 2.20
Symptom severity factor (items 1,4,5,6,9,10) 12.54 ± 3.76 (7.80 ± 3.72) 0.09
3-factor model [58] Obsession severity
factor (items 1–3,5)
9.54 ± 2.74 (6.13 ± 2.90) 0.37 8.19 1 0.004 1.45 1.12 1.87
Resistance factor (items 4,9) 3.86 ± 1.36 (2.30 ± 1.37) 0.59 5.16 1 0.023 1.82 1.08 3.02
Compulsion severity factor (items 6–8,10) 7.82 ± 3.51 (4.30 ± 3.17) 0.25
Predicted group = the group coded with value 1 in binary regression analysis; NR non-responders, R responders; Significant results are highlighted (p ≤ 0.05)
in bold
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OFC) that were not adequately modulated by SMA or
DLPFC rTMS. The rationale for targeting SMA and
DLPFC with these protocols is related to the activation
pattern of these regions in OCD. The SMA and right
DLPFC that have extensive connections with regions im-
plicated in cognitive processes and motor control and
response inhibition [62, 63], show hyperactivation in
OCD patients. The 1 Hz stimulation applied over the
SMA and right DLPFC has an inhibitory effect and is
thus expected to reduce activation in these regions [43].
On the other hand, the left DLPFC is involved in cogni-
tive control [64] and increasing its activation with NIBS
has been associated with improved control over intrusive
thoughts in OCD [36] and cognitive control in other dis-
orders marked with executive dysfunctions [15, 17, 19,
65]. Increasing the left DLPFC with excitatory and right
DLPFC with inhibitory stimulation is in line with the pu-
tative regions that are affected in OCD and involved in
cognitive control and response inhibition/affect respect-
ively [10]. Nevertheless, whether and how these proto-
cols are effective in OCD patients depends on the
individualized stimulation protocol taking into account
the underlying pathophysiology, relevant symptoms, and
comorbid diagnosis.
The length and number of rTMS sessions can also
affect the response rate, with a higher number of ses-
sions providing more symptom reduction [31, 66]. Our
findings support this assumption since we observed a
significant reduction of Y-BOCS scores even in non-
responders with a relatively intensive intervention proto-
col. Here, however, results should be interpreted with
caution due to the lack of sham condition which does
not allow to rule out a potential placebo effect, if any,
despite the baseline-control condition we have. Further-
more, similar efficacy of DLPFC vs SMA rTMS proto-
cols should be considered in the absence of
demographic and questionnaire-based group differences.
Although allocation to DLPFC protocol was based on
one higher report of affective states in patients, no sig-
nificant difference was found between the patients in the
baseline depressive scores based on the BDI-II. Future
studies should apply a more strict cut-off point, using
objective measures, for determining depression states
and group allocation accordingly.
Our finding of the absence of relevant demographic
predictors of rTMS response is in line with a recent re-
port of a missing correlation between baseline psycho-
metric factors, including age, and rTMS treatment
outcome [9]. Age, however, seems to be a predictor of
rTMS response in depression [67–70]. Regarding clinical
predictors, our model showed that significant factors
and items that predicted response to rTMS were related
to both obsession and compulsion although the weight
of obsession-related factors/items appears to be more as
far as the results f the regression analyses are concerned.
The obsession severity, resistance and “disturbance” were
the factors with the highest predictive ability in rTMS
response and the last two factors (resistance, disturbance
factors) include items related to both obsession and
compulsion. Our model based on Y-BOCS items showed
a similar pattern of predictors. Specifically, we found
that higher scores in “interference due to obsessions”
(item 2), which is related to disturbance factor, and “re-
sistance against compulsion” (item 9), related to the re-
sistance factor, determined response failure to rTMS
treatment. The common factor underlying both obses-
sion and compulsion related items is the disturbance
factor and this implicates that those OCD symptoms (in-
cluding both obsession and compulsion-related ones)
that result in more disturbance/interference are import-
ant in predicting response to rTMS.
The predictive value of these factors and relevant
items could have clinical implications for treatment re-
sponse. Patients with more “severe obsessions” have
more intrusive thoughts and experience greater overall
difficulties due to obsession interference [34, 71]. This is
in line with recent findings showing that obsessions are
usually not targeted by rTMS protocols while they are
important in determining treatment response and thus
should be primarily targeted in future interventions [72].
Furthermore, the relationship between intrusive
thoughts and development and maintenance of OCD
symptoms [73] might also explain why severe obsessive
symptoms hinder response to rTMS treatment. This,
however, should not implicate that compulsions are not
important. Indeed, the “disturbance” factor, which is the
strongest predictor among the factors, is related to dis-
tress and interference in both obsession and compulsion
indicative of [57]. The “resistance” factor similarly re-
flects the severity of both obsessive and compulsive
symptoms that are difficult to overcome [57, 58, 74].
Items related to the “resistance” factor, do not signifi-
cantly change after pharmacological treatment [58, 75].
Taken together, these factors and the relevant items in-
dicate that the severity of symptoms and the level of
interference and disturbance caused by OCD symptoms
(related to both obsession and compulsions) are negative
predictors of rTMS response.
Since these aspects of OCD symptoms seem to be of
utmost importance for response failure to rTMS treat-
ment, it might on the one hand help to decide about
therapeutic options in specific patients. On the other
hand, it also suggests that patients with a lower probabil-
ity for successful rTMS treatment with conventional
protocols might require alternative interventions. In this
line, one important implication of our findings is the
need for adapting rTMS protocols to patients’ symp-
toms. According to our results, high levels of the
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interference, disturbance and resistance aspects of OCD
symptoms have a negative impact on rTMS response.
Patients with prominent symptoms related to these fac-
tors might benefit more from protocols that are opti-
mized to have a strong impact on interference or
inhibition. An alternative option might be to treat these
patients with a treatment approach focused on improv-
ing cognitive control strategies over both obsessions and
compulsions [76]. For example, treatment strategies that
are focused on improving appraisal and control strat-
egies in response to intrusive thoughts, which are associ-
ated with distress and interference [77–80], might be
beneficial to OCD patients who fail to respond to rTMS
due to being highly disturbed by intrusive thoughts and
compulsions.
Our findings are preliminary, and this study has some
limitations. The major limitation of our analysis is the
retrospective study design. Nevertheless, our data has
relatively high ecological validity and provides a realistic
picture of rTMS application in clinical settings. Sec-
ondly, our control condition is limited to a baseline-
control and lacks a sham intervention condition. Un-
blinded assessment by multiple raters, which could be a
source of bias, and inter-rater variability, are other limi-
tations of our work. Although the sample size was large
enough for investigating the efficacy of rTMS, it may
have been relatively underpowered for obtaining robust
results by the regression analysis performed on individ-
ual items of the Y-BOCS. Sample size, however, was suf-
ficiently large for factor-based regression analysis, which
resulted in similar clinical predictors of rTMS response.
The use of 120% of active rather than resting motor
threshold could be a limiting factor in determining re-
sponse rate as rTMS at AMT intensity usually delivers
underdosage stimulation compared to RMT [81]. Alloca-
tion to rTMS protocols (DLPFC vs SMA) based on the
prominence of depressive states determined by clinical
impression and mere self-reports should be improved in
future studies by applying higher cut-off points. Lastly,
although we kept the medication dosage constant 8-10
weeks before the experiment and throughout the inter-
vention (4–6 weeks) to minimize potential confounding
and interference, and this factor did not predict response
status, it should be controlled directly in future studies,
as it might be a potential source of variability of rTMS
effects.
Conclusions
Our findings identified some important predictors of
therapeutic efficacy of rTMS in OCD, which might help
to develop adaptive and personalized stimulation proto-
cols in future. Specifically, patients with severe obsession
symptoms and higher dysfunctions due to intrusive
thoughts, more distress and less control over compulsive
behaviors might not be good candidates for receiving
DLPFC and/ or SMA rTMS treatment.
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